Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2018-04-18 Proxy Solicitation & In…
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the Annual Meeting of Stockholders, voting instructions, director nominations, and ratification of the independent auditor. The document is titled 'Definitive Additional Materials' related to the proxy statement and contains no financial statements or detailed financial analysis. It is not the proxy statement itself but additional materials related to it. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is over 6,000 characters, indicating it is substantive and not just a brief announcement. Hence, the classification is PSI with high confidence.
2018-04-18 English
>DEF 14A
Proxy Solicitation & Information Statement
2018-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2018-04-03 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-28 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2018, by Protagonist Therapeutics, Inc. It announces the discontinuation of a Phase 2b clinical study based on interim analysis results. The content is an event disclosure rather than a financial report or earnings release. The document is short (3693 characters) and focuses on a specific corporate event (clinical trial discontinuation). This fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-03-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.